ClinicalTrials.gg
RecruitingNCT07467109Updated Sep 9, 2026

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers

An observational study in Intracranial Venous Blood, Brain Cancers and Liquid Biopsy, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by M.D. Anderson Cancer Center · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Brain Neoplasms by M.D. Anderson Cancer Center — 13 open to participants now, 30 under way, 3 of them phase 3. Brain Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
8th of 13
20 · median 30
Started
2026
with 2 others
Observational
13 of 87
3 open now
Primary completion
2027-05
later than 11 of 29 live
Registered
86th of 87
by date

Among the 87 studies in Brain Neoplasms by M.D. Anderson Cancer Center, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2026, is one of 13 observational ones, reaches primary completion later than 11 of the 29 other live ones, and was the 86th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

13 of the 87 studies in Brain Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Brain Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

To learn if drawing blood directly from veins inside the brain is safe and can effectively provide the same kind of detailed information about high-grade glioma as traditional surgical biopsy.

Read the detailed description

Primary Objectives The primary objective is to evaluate the safety and efficacy of intracranial venous sampling with or without BBB disruption with administration of intraarterial mannitol in participants with high grade gliomas.

  • The study will determine if intracranial venous blood sampling for liquid biopsy can facilitate accurate and precise molecular diagnosis in participants with high grade gliomas that is comparable to molecular diagnosis obtained during surgical brain biopsy.
  • The study will determine if intracranial venous blood sampling for liquid biopsy requires concomitant temporary blood brain barrier disruption with endovascular selective intraarterial infusion of mannitol for accurate and precise molecular diagnosis of high-grade gliomas.

Secondary Objectives

  • The study will determine if intracranial venous blood sampling in participants with high grade gliomas results in higher yield of ctDNA and other biomarkers than peripheral venous blood sampling, and if this is further augmented by BBB disruption.
03

Conditions studied

  • Intracranial Venous Blood
  • Brain Cancers
  • Liquid Biopsy
  • Evaluate the Safety

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

MD Anderson Cancer Center

Eligibility criteria

Eligibility Criteria

  1. Subjects over the age of 18 with suspected or confirmed, recently diagnosed, previously treated or recurrent high-grade glioma (WHO grade III and IV) in whom a diagnostic cerebral Angiogram is indicated as standard of care may be approached for participation in this study.
  2. Subjects are eligible if review of relevant intracranial cerebrovascular anatomy by cross sectional imaging such as CTA head and MRI brain, is deemed suitable for endovascular intracranial venous sampling.
  3. For subjects with suspected or recently diagnosed glioma, subjects are eligible if they have or are scheduled to undergo surgical or surgical resection of the tumor within 4 weeks (+/- 1 week) of the planned liquid biopsy.
  4. For subjects with previously treated or recurrent glioma in whom tissue diagnosis and molecular profiling had been previously performed on surgical specimens at any time in the past, a planned surgical biopsy/resection is desirable but not necessary for inclusion in the study.

    • Ability to understand and the willingness to sign an document.
  5. For participants with known history of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy within 6 months, if indicated.
  6. Participants with a history of virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load within 6 months.
  7. Participants with a known history of (HIV on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  8. Performance Scale ≥ 60%
  9. Participants must have adequate organ and marrow function as defined below:

≥ 7mg/dL ≥ 1,000/mcL ≥ 100,000/mcL ≤ 1.7 (SGOT)/ALT(SGPT) ≤3 × institutional creatinine ≤ 1.5mg/dL

Exclusion Criteria

  1. Subjects with suspected glioma or other brain cancers who do not have a tissue diagnosis and no surgical biopsy or resection is anticipated.
  2. Subjects in whom diagnostic cerebral angiogram is defined as:

    • Severe contrast allergy
    • Acute/chronic renal dysfunction with \< 45 ml/min and Cr ≤ 1.5 mg/dL
  3. For participants undergoing surgery, coagulopathy or thrombocytopenia which cannot be corrected defined as:

    • Platelets ≤100,000/mcL
    • International Normalized Ratio ≤ 1.7
  4. Subjects that have a known high risk in monitored anesthetic care or general anesthesia assessed by the treating physician.
  5. Anatomic considerations: based on cross-sectional imaging such as CT angiogram of the head and neck, the anatomy for arterial and venous vascular access is deemed unsuitable for endovascular access such as high-grade carotid artery stenosis, absent or occluded internal jugular veins, sigmoid sinuses and/or transverse sinuses.
  6. Participants with clinical cerebral edema evidenced from altered mental status
  7. Pregnant women due to risk of radiation exposure to the fetus, as determined by pregnancy urinalysis or serum analysis test during screening.
  8. Subjects with psychiatric illness/social situations that would limit compliance with study requirements at the physician's discretion.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intracranial Venous Blood Sampling With BBB Disruption

    Comparisons will be made between the peripheral, intracranial venous blood and intracranial arterial blood, before and after BBB disruption to evaluate the amount of ctDNA and the degree of concordance between molecular markers for tumor diagnosis.

    Diagnostic Test: blood sampling

Interventions

  • Diagnostic testblood sampling

    Done by IV

06

What researchers measure

Primary outcomes

  1. safety and adverse events (AEs).

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 12 months is below that.

Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 12, 2026
StartActual
Apr 13, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2029
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07467109
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Apr 13, 2026
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Sep 9, 2026

Study contacts

Christopher C Young, MD
Contact
ccyoung1@mdanderson.org
713-745-4243
Christopher C Young, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion